Le Lézard
Classified in: Health, Business
Subjects: PER, VEN

Versameb Raises CHF 6.4 Million in Seed C Round and Strengthens the Team


BASEL, Switzerland, Oct. 17, 2019 /PRNewswire/ -- Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.

The proceeds of this financing round will be used to expand the company's proprietary technology platform, VERSagile, in multiple indications and advance the lead program towards clinical studies. The VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in various therapeutic indications.

"We are very pleased and grateful to see the interest of new investors, as well as the strong confidence shown by our existing shareholders," said Prof. Dr. Friedrich Metzger, CEO of Versameb.

Team strengthened with new Chairman of the Board and Chief Business Officer

At the 2019 Annual Shareholder Meeting, Dr. Reinhard Ambros was elected as a Member of the Board of Directors and was subsequently appointed Chairman succeeding Roger Meier. Reinhard has built the Novartis Venture Fund to a leading corporate biotech venture fund and has held various leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical drug development. His exceptional professional experience adds relevant expertise and insight to Versameb's Board of Directors.

Reinhard Ambros commented: "I was attracted to join Versameb because I see a great potential in its unique mRNA technology platform and the ambitious goals to develop next-generation RNA therapies. I look forward to serve as Chairman of the Board and work with this outstanding team to play a part in Versameb's future development."

In addition, Versameb has recently appointed Dr. Isabel Ferreira as Chief Business Officer. In her role, Isabel Ferreira will be responsible for leading the company's global partnering and corporate development strategy and execution. Isabel Ferreira served most recently in Roche Partnering as Director Global Business Development, led strategic projects and cross-functional teams to deal closure. Prior to joining Roche, she acted as Senior Director Business Development in a Dutch Biotech company that was listed on NASDAQ in a successful IPO in 2013 and was acquired by BioMarin early 2015.

"I am excited to welcome Reinhard and Isabel to our team. Their extensive experience and successful track record deepen our business expertise as we take the company to the next level and execute on our growth strategy," said Friedrich Metzger, CEO of Versameb. "On behalf of the Board, I also thank Roger for his guidance and leadership over the past two years, helping us to successfully grow the company. I am very pleased that he will continue to support us on the Board of Directors."

About Versameb AG

Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team.

The company's focus is the development of novel RNA-based therapeutics. Versameb's proprietary VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in multiple disease areas with high unmet medical need.

For more information, please visit www.versameb.com.

Contact for Media Enquiries

Tatsuo Satoh
Operations Director
Versameb AG
Hochbergerstrasse 60C
CH-4058 Basel
+41-61-638-23-56
+41-78-819-17-44
[email protected]

SOURCE Versameb AG


These press releases may also interest you

at 21:00
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today published a report titled 'Unlocking the Infinite Potential of Crypto and AI.' The report explores the convergence of AI and crypto, a major trend in...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:45
The "Austria Social Commerce Market Intelligence and Future Growth Dynamics Databook - 50+ KPIs on Social Commerce Trends by End-Use Sectors, Operational KPIs, Retail Product Dynamics, and Consumer Demographics - Q1 2024 Update" report has been added...

at 20:40
Osisko Development Corp. ("Osisko Development" or the "Company") reports its financial and operating results for the three and twelve months ended December 31, 2023 ("Q4 2023"). Q4 2023 HIGHLIGHTS Operating, Financial and Corporate Updates: 2,090...

at 20:39
TSX VENTURE COMPANIES BULLETIN V2024-0926 VALLEYVIEW RESOURCES LTD. ("VVR")BULLETIN TYPE:  Resume TradingBULLETIN DATE: March 28, 2024TSX Venture Tier 2 Company Reference is made to our bulletin dated March 26, 2024 with respect to the listing of the...

at 20:30
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sonder Holdings Inc. resulting from allegations that Sonder may have issued materially misleading business...



News published on and distributed by: